Search Results

✳️Celtarys is ready to support your assay development. Get to know more: Celtarys Research | Dr. ✳️Celtarys is ready to support your assay development. Get to know more: Celtarys Research | Dr.

GPCR to support assay development worldwide. GPCR to support assay development worldwide.

Discover how Celtarys Research is transforming GPCR assay development with fluorescent ligands in this probes for GPCR assays. GPCR, Celtarys will bring those lessons to the broader community, providing insight into assay development Whether you're designing assays, developing probes, or seeking better tools for GPCR drug discovery, , GPCR assay development , G protein-coupled receptors , GPCR podcast , Celtarys partnership Summary

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights This conversation is especially valuable for scientists developing functional assays, fluorescence-based What early cyclic AMP assays revealed about spatial signaling long before high-content technologies existed development and GPCR research. ⸻ Why It Might Hit Home If you’ve ever: Faced unexpected assay behavior Get behind-the-scenes conversations, advanced assay development strategies, and practical GPCR tools

David has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development role and most recently with Novartis. His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

His current work is mainly focused on screening and assay development to bridge the gap between in vitro

Eric Trinquet shares the inside story behind the development of pH Sense, Revvity’s latest innovation and product development, Eric takes us through the highs, failures, and scientific “aha” moments that advancing GPCR research. ⸻ Inside This Episode How Eric and his team reimagined rare earth complexes to develop and hit the “overexpression ceiling,” Balanced scientific rigor with the unpredictability of product development development.

His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic design. on biological context Balanced innovation with the need for reproducible, well-controlled functional assays His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within

Johannes Broichhagen reveals how fluorescent probes transform GPCR imaging, internalization studies, and assay development in live cells and tissues. << Back to podcast list Strategic Partner(s) Chemical Probes Balanced creativity in tool development with the pressure for reproducible, publication-grade data. Tried to build assays that behave in living cells—not just on paper. research group at the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin, focusing on developing

Podcast , leaders from academia and biotech unpack what effective collaboration really looks like when developing development benefits from scalable distribution rather than ad-hoc sharing. Listen This episode is for scientists and leaders who are: Navigating the transition from academic tool development co-founding the company in 2021, she has led all scientific activities, from proprietary technology development His research focuses on bottom-up chemical tool development for imaging and interrogating GPCRs and other

for receptor activator and continuously work to identify novel chemical modulators of AGPCRs through assay development and high-throughput screening efforts. I have previous work experience at two separate contract research organizations centered on assay development

Accelerated Program Progression: Design robust assay cascades and establish key go/no-go points to speed Define Actionable Objectives Together, we clarify specific, measurable goals, from target validation and assay development to CRO selection or portfolio strategy, ensuring a tailored approach. 3 Collaborative Execution Accelerated Preclinical Progression I streamline critical operational processes, from advanced assay Small missteps can derail entire programs: underperforming assays, off-track CROs, and data that fails

🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We We solve assay problems.” – Dr. 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research We solve assay problems.” – Dr.

Check out the development of a NanoBRET assay platform to detect intracellular ligands for the chemokine Check out the development of a NanoBRET assay platform to detect intracellular ligands for the chemokine ➡️ https://www.ecosystem.drgpcr.com/methods-and-updates-in-gpcr-research/development-of-a-nanobret-assay-platform-to-detect-intracellular-ligands-for-the-chemokine-receptors-ccr6

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics solutions for basic research through therapeutic discovery and development. Assay Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic drugs, Eurofins DiscoverX provides you with a variety of drug discovery and development custom product solutions represent the foundation of tools for GPCR research and drug discovery and development

Tom Sakmar and Ilana Kotliar about how their lab developed: A multiplexed Luminex assay to screen hundreds Tom Sakmar and Ilana Kotliar about how their lab developed: A multiplexed Luminex assay to screen hundreds

By using signalling assays, radioligand binding assay, and microscopy, Gaidarov et al. suggested that By using signalling assays, radioligand binding assay, and microscopy, Gaidarov et al. suggested that

Home → Flash News → 🚨 Exciting Opportunity for Professionals in Drug Development! GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to GPCR Courses 🚨 Exciting Opportunity for Professionals in Drug Development! Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to

He currently leads Revvity's Research and Development activities, focusing on biochemical and cellular Before joining Revvity, Eric worked for Cisbio Bioassays first as Director of Technological Development department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma, Eric Trinquet, Director of Research and Development at Revvity. ™ was developed to overcome three persistent barriers in internalization studies: Complexity of imaging-based

Home → Flash News → Exploring the combination of molecular simulation, pharmacological assays, and NMR , 2024 Category GPCR Weekly News Exploring the combination of molecular simulation, pharmacological assays

Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties GPCR Functional Assay Fluorescent GTPγS enables sensitive, non-radioactive GPCR activity assays for drug Custom Development Tailored fluorescent probes designed for unique research requirements.

During my PhD, I learnt radioligand binding assays, behavioral assays, autoradiography, stereotaxic surgeries nervous system disorders realm to understand the neurobiology of neuropsychiatric disorders and to develop

Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Howard Hughes Medical Institute appointment, Tom advanced a series of novel biochemical and biophysical assay Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids Early applications included “targeted photo-crosslinking,” and more recently, the parallel development

The conversation ended with Arthur's ongoing research and his development of a new operational model. Allosteric Modulation and Hybrid Molecules Arthur and Yamina discussed the development of an operational Arthur recounted a 2004 visit to a pharma company using replicates in assays. also discussed the potential of certain drugs, like flumazenil, as 'nails' or compounds that could be developed and Reproducibility Yamina and Arthur discussed the concept of a target product profile (TPP) in drug development

Ilana Kotliar , his former graduate student, to explore the development of powerful multiplex tools designed Curiosity to Collaboration “We decided to evaluate the multiplexing methods... and found this Luminex assay ” – Tom Sakmar After exploring several screening techniques, the lab adopted the Luminex bead-based assay the Community “We have a library on Addgene... dual-epitope tagged GPCRs.” – Ilana Kotliar The team developed Keyword Cloud GPCR-RAMP interactions , multiplex assays , GPCR research community , Dr.

Karine Pichavant , I contributed to the development of a drug to treat hypovolemic shock after severe MRAP2 regulates GHSR1a signaling; this project brought forth our NanoBiT-based arrestin recruitment assay This powerful tool allowed us to create an assay that kinetically measured the arrestin recruitment to Chemistry which described the molecular mechanisms of MRAP2 regulation of the GHSR1a, and where I notably developed I also invested a tremendous amount of time in developing my leadership skills.

Whether you’re refining assay strategy or evaluating data, these lessons give you the tools to think Yamina’s Corner—GPCR consulting to de-risk and accelerate your pipeline ♦️ Celtarys’ validated TR-FRET assay

GPCR Podcast Back when GPCR assays were performed with single channel pipettes, failure wasn’t cheap. Michelle Halls still remembers pipetting one sample at a time, holding her breath to keep the assay alive

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation

biotech company specializing in fluorescent ligand technologies and real-time, non-radioactive GPCR assays biotech company specializing in fluorescent ligand technologies and real-time, non-radioactive GPCR assays affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development